Published in J Virol on December 12, 2012
A conserved NS3 surface patch orchestrates NS2 protease stimulation, NS5A hyperphosphorylation and HCV genome replication. PLoS Pathog (2015) 1.46
Insights into the complexity and functionality of hepatitis C virus NS5A phosphorylation. J Virol (2013) 1.04
Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-α in infectious virus production. J Virol (2014) 1.00
Genetic complementation of hepatitis C virus nonstructural protein functions associated with replication exhibits requirements that differ from those for virion assembly. J Virol (2013) 0.82
Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins. PLoS Pathog (2015) 0.80
Phosphoproteomics Identified an NS5A Phosphorylation Site Involved in Hepatitis C Virus Replication. J Biol Chem (2015) 0.79
Vinexin β Interacts with Hepatitis C Virus NS5A, Modulating Its Hyperphosphorylation To Regulate Viral Propagation. J Virol (2015) 0.78
Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases. PLoS One (2016) 0.78
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med (2015) 0.77
Serine 235 Is the Primary NS5A Hyper-Phosphorylation Site Responsible for HCV Replication. J Virol (2017) 0.76
Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation. J Virol (2015) 0.76
Synergistic Activity of Combined NS5A Inhibitors. Antimicrob Agents Chemother (2015) 0.75
Polyprotein-Driven Formation of Two Interdependent Sets of Complexes Supporting Hepatitis C Virus Genome Replication. J Virol (2015) 0.75
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem (2001) 3.91
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog (2008) 3.81
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog (2008) 3.77
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol (1995) 3.41
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun (1994) 2.89
Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol (2003) 2.86
Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008) 2.74
Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem (2004) 2.71
Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem (2005) 2.61
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol (2009) 2.39
Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol (1999) 2.26
Wrapping things up about virus RNA replication. Traffic (2005) 2.00
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol (1999) 1.75
Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology (2007) 1.74
Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol (2004) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol (2009) 1.64
Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry (2007) 1.53
Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. J Virol (2005) 1.47
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Hepatitis C viral life cycle. Adv Drug Deliv Rev (2007) 1.41
All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol (2010) 1.37
Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun (2009) 1.34
Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem (2011) 1.32
The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One (2011) 1.19
Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol (2010) 1.15
Genetic interactions between hepatitis C virus replicons. J Virol (2004) 1.14
New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis (2010) 1.13
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility. J Virol (2012) 1.02
Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem (2012) 1.01
Trans-complementation of HCV replication by non-structural protein 5A. Virus Res (2005) 0.99
Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63). Biochem J (1994) 0.94
A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol (2008) 0.93
TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future (2011) 0.83
Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271. Mol Biol Cell (2010) 0.82
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 7.91
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Axon regeneration in young adult mice lacking Nogo-A/B. Neuron (2003) 4.23
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A (2003) 3.38
A role for small RNAs in DNA double-strand break repair. Cell (2012) 3.15
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
True versus reported waiting times for valvular aortic stenosis surgery. Can J Cardiol (2006) 2.21
Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol (2007) 2.11
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A (2002) 1.96
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol (2004) 1.93
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J (2003) 1.72
Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol (2002) 1.68
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol (2002) 1.47
Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46
Small intestinal hemolymphangioma with bleeding: a case report. World J Gastroenterol (2012) 1.45
Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res (2006) 1.45
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41
The mortality rate from anorexia nervosa. Int J Eat Disord (2005) 1.40
Trends in wait times for cardiac revascularization. Can J Cardiol (2011) 1.39
Percutaneous coronary intervention and 30-day mortality: the British Columbia PCI risk score. Catheter Cardiovasc Interv (2009) 1.37
Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology (2006) 1.36
Specific inhibition of bovine viral diarrhea virus replicase. J Virol (2003) 1.28
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet (2008) 1.26
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology (2013) 1.24
Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22
Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest (2006) 1.21
Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density. J Cell Biol (2002) 1.20
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Outcome of mitral valve repair or replacement: a comparison by propensity score analysis. Circulation (2003) 1.19
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet (2012) 1.12
Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis (2009) 1.12
Evolution and expression analysis of the grape (Vitis vinifera L.) WRKY gene family. J Exp Bot (2014) 1.11
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother (2013) 1.11
Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Womens Health (Larchmt) (2013) 1.11
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res (2012) 1.07
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum (2010) 1.03
Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J (2013) 1.02
Multi-detector CT enterography with iso-osmotic mannitol as oral contrast for detecting small bowel disease. World J Gastroenterol (2005) 1.01
A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet (2005) 1.00
Genomic organization, phylogenetic comparison and differential expression of the SBP-box family genes in grape. PLoS One (2013) 1.00
Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol (2012) 0.98
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Revascularization use and survival outcomes after cardiac catheterization in British Columbia and Alberta. Can J Cardiol (2004) 0.97
Defining NOTCH3 target genes in ovarian cancer. Cancer Res (2012) 0.97
Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol (2007) 0.96
Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol (2012) 0.96
Genome-wide identification and analysis of the TIFY gene family in grape. PLoS One (2012) 0.95
In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother (2002) 0.95
Characterizations of HCV NS5A replication complex inhibitors. Virology (2013) 0.95
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion (2009) 0.94
Growth and performance of yttrium oxide as an ideal high-kappa gate dielectric for carbon-based electronics. Nano Lett (2010) 0.94
Nogo-C is sufficient to delay nerve regeneration. Mol Cell Neurosci (2003) 0.94
The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One (2013) 0.93
Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China. Chin Med J (Engl) (2005) 0.93
Aortic arch reconstruction: safety of moderate hypothermia and antegrade cerebral perfusion during systemic circulatory arrest. J Card Surg (2006) 0.93
FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal (2012) 0.92
Amphiphilic self-assembly of an n-type nanotube. Angew Chem Int Ed Engl (2010) 0.92